Slides
Page 1
1 Investor Presentation Q2 and H1 FY2027 November 3, 2026 GLOBAL HEALTH LIMITED Dedicated to Life 5
Page 2
2 Disclaimer This presentation, apart from historical information, contains some "forward-looking statements" including those describing the Company’s strategies, strategic direction, objectives, future prospects, estimates etc. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by these statements. These factors include, but are not limited to general market conditions, macro-economic, movements in currency exchange and interest rates, the ability to attract and retain high quality human resource, competitive pressures, technological developments, governmental and regulatory trends, legislative developments, and other key factors beyond the control of the Company. These forward looking statements are based on information currently available to us, and we assume no obligation to revise these statements as circumstances change. The Company may alter, modify or otherwise change in any manner the content of Presentation/Press Release, without obligation to notify any person of such revision or changes. I • •
Page 3
3 Contents Q2 and H1 FY2027 Performance Update01 Project Update and Capex Plan02 Medanta’s Journey, Purpose and Model of Healthcare03 Annexures04
Page 4
4 Q2 and H1 FY2027 Performance Update01
Page 5
5 Q2 FY2027 performance summary Revenue Growth of 34% y-o-y driven by growth in patient volumes *ARPP is calculated on Hospital Revenues excluding Other Operating Income and other income divided by Inpatient Volumes; **Outpatients volume reflects OPD encounters Occupied Bed Days 190,600 ARPP* (INR Lakh) ALOS (days) 2.06 Q2 FY26 155,729 22.4% Q2 FY26 2.01 2.7% Patient Footfalls (in ‘000) 29.5% 37.9% 66 In-patients 1,229 Out-patients** Q2 FY26 51 Q2 FY26 891 Revenue from operations Q2 FY26 10,993 million 33.6% Operating EBITDA1 and Margins % INR 3,701 million Margin: 25.2% Q2 FY26 2,310 million Margin: 21.0% 60.2% PAT and Margins % Q2 FY26 1,584 million Margin: 14.4% 38.3% INR 14,690 million INR 2,191 million Margin: 14.9% 2.89 Q2 FY26 3.06 -5.5% 1. Operating EBITDA is defined as EBITDA excluding other income and after accounting for ESOP expenses. The comparative figures have also been presented on a consistent, like-for-like basis ~ +meoama ~ ~ ~ ~ ~ ~ ~ ~ ... ~ ~ ~ ~ I ~ ~ ~ ~ ~ ~ ~ ... ~ ~ ~ ~ I ~ ~ ~ ~
Page 6
6 Q2 FY2027 performance summary Revenue Growth of 34% y-o-y, primarily led by increase in patient volumes Q2FY27 revenue from operations of INR 14,690 million; growth of 33.6% y-o-y Operating EBITDA grew 60.2 % y-o-y to INR 3,701 million with improved margins of 25.2% in Q2 FY27 compared to 21.0% in Q2FY26. Noida hospital witnessed revenue from operations of INR 1,059 million and EBITDA of INR 86 million in Q2 FY27 Profit After Tax was INR 2,191 million, compared to INR 1,584 million in Q2FY26. PAT margins were at 14.9% compared to 14.4% in Q2 FY26 During the quarter, total 74 new beds were added across the network; 25 beds were added at Lucknow and 49 beds in Noida Medanta continues to witness robust volume growth, In-patient count grew by 29.5% while Out-patient count grew by 37.9% y-o-y With the addition of beds across the network over the last 18 months (including Noida launch), Medanta’s Census bed capacity stood at 3,115 in Q2FY27 compared to 2,658 beds in Q2FY26. Occupied bed days increased by 22.4% y-o-y, representing an occupancy of ~67% on increased bed capacity compared to 64% in Q2FY26. Average revenue per patient (ARPP) for the quarter was INR 2.06 lakh compared to INR 2.01 lakh in Q2FY26 Average length of stay (ALOS) for the quarter was 2.89 days compared to 3.06 days in previous corresponding quarter Cluster 1 hospitals (Gurgaon, Indore and Ranchi) reported revenue from operations of INR 8,229 million in Q2FY27, growth of 17.8% y-o-y. Operating EBITDA was INR 1,810 million, growth of 29.1% y-o-y; Operating EBITDA margin expanded to 22.0% from 20.1% in Q2FY26. Cluster 2 hospitals (Lucknow, Patna and Noida), reported revenue from operations of INR 5,790 million, growth of 63.2% y-o-y. Operating EBITDA increased by 110.0% y-o-y to INR 1,837 million, with margins improving to 31.7% compared to 24.7% in Q2FY26 During the quarter, International Patients Revenue increased by 30.3% y-o-y to INR 993 million OPD Pharmacy (Hospital & Retail) business continues to witness robust growth. Revenue increased by 52.9% y-o-y to INR 699 million in Q2 FY27 1. EBITDA represents EBITDA before ESOP expenses
Page 7
7 Q2 FY2027 Business update Strengthening the Core and Building a Robust Pipeline for Sustainable Growth Capacity Expansion 100+ Doctors on-boarded in Q2 FY27 across Medanta network hospitals 65+ senior clinicians on-boarded during the quarter Attract Best Talent Noida: Added 49 beds; total operational capacity at 482 beds Lucknow: 25 beds added, taking total bed capacity to 803 beds Ranchi: Launched Medical Oncology services Gurugram: 2 New OTs and 1 new Cath Lab added during the quarter Ghaziabad: Allotted 2.61 acre land parcel in an e-auction for INR 1,658.2 mn 850+ active collection centres across 120+ cities supported by 13 labs and 7 HLMs /RLMs Added 6 pharmacies during the quarter, expanding the network to 28 operational pharmacies (7 Hospital, 4 Medi-clinics and 17 Retail Pharmacies) Continuity of Care New Medical Equipment Deployed Siemens Artis ceiling-mounted cath lab VELYS Hip Navigation Station SAT Station BAS Station PatnaGurugram Artis Icono Biplane Lab
Page 8
8 Noida operations demonstrating strong momentum, with EBITDA breakeven achieved during Q2 FY27 Revenue from operations (INR million) Operating EBITDA1 (INR million) Medanta Noida operational with 482 beds 37 341 525 855 1,059 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 -199 -321 -236 -49 86 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 1. Operating EBITDA is defined as EBITDA excluding other income and after accounting for ESOP expenses. The comparative figures have also been presented on a consistent, like-for-like basis.
Page 9
9 Key operating metrics: Revenue and profitability Operating EBITDA in Q2 and H1 grew by 60% and 43% y-o-y, respectively Revenue from operations (INR million) Operating EBITDA1 (INR million and margin %) 4,580 6,568 2,310 2,868 H1 FY26 H1 FY27 Q2 FY26 Q1 FY27 Q2 FY27 3,701 +43.4% +60.2% 21.5% 21.0% 22.0% 21,301 27,731 10,993 13,041 H1 FY26 H1 FY27 Q2 FY26 Q1 FY27 Q2 FY27 14,690 +30.2% +33.6% 23.7% 25.2% 1. Operating EBITDA is defined as EBITDA excluding other income and after accounting for ESOP expenses. The comparative figures have also been presented on a consistent, like-for-like basis ~ +meoama~ ~ ~ ~ ~ ~ C ~ + ~ ~ ~ ~ + ~ ~ ~ -= ~ ~ ~ ~ ~ ~ C ~ ~ + ~ ~ + ~ ~ ~ .. ~ ~ ~ ~ ~
Page 10
10 Key operating metrics: Profitability and margin Q2 PBT and PAT growth of 48% and 38% y-o-y, respectively Profit before tax (INR million and margin %) 4,080 5,081 1,998 2,133 H1 FY26* H1 FY27 Q2 FY26* Q1 FY27 Q2 FY27 2,948 +24.5% +47.6% Profit after tax (INR million and margin %) H1 FY26* H1 FY27 Q1 FY27 Q2 FY27 3,174 3,764 1,584 1,573 2,191 Q2 FY26* +18.6% +38.3% 14.9% 14.4% 12.1% 14.9% 19.2% 18.2% 16.4% 20.1% 13.6% 18.3% *Q2FY26 and H1FY26 PBT includes a non-recurring exceptional income of INR 160 million and INR 356 million, respectively, on account of 1) reversal of potential interest liability on EPCG following transfer of EPCG licenses from MHPL to GHL amounting to INR 196 million (accounted in Q1FY26) and 2) reversal of stamp duty payable on account of the mergerof MHPL with GHL, amounting to INR 159.85 million pursuant to adjudication of its stamp duty application (accounted in Q2FY26). ~ +meoama~ ~ ~ ~ ~ ~ ~ + ~ ~ ~ + ~ ~ ~ ~ ~ ~ ~ c=:> c::::> c=:> c=:> c::::> ~ ~ ~ ~ ~ ~ ~ c=:> + ~ ~ ~ ~ ~ ~ ~ c=:> c=:> ~ ~
Page 11
11 Key operating metrics: Volumes, occupancies, ALOS Average census and occupied beds per day 64% 63% 67% 3.04 2.88 3.06 2.87 2.89 H1 FY26 H1 FY27 Q2 FY26 Q1 FY27 Q2 FY27 -5.3% -5.5% ALOS (days) OPD volumes* (in ‘000) 1,710 2,330 891 1,101 1,229 H1 FY26 H1 FY27 Q2 FY26 Q1 FY27 Q2 FY27 +36.3% +37.9%98 126 51 60 66 H1 FY26 H1 FY27 Q2 FY26 Q1 FY27 Q2 FY27 +28.6% +29.5% IPD volumes (in ‘000) 2,573 3,076 2,658 3,037 3,115 1,632 1,987 1,693 1,902 2,072 H1 FY26 H1 FY27 Q2 FY26 Q1 FY27 Q2 FY27 +21.8% +17.2% +22.4% Census beds Occupied beds 63% 65% * OPD volumes reflects OPD encounters Q2 FY27 witnessed 17% expansion in census bed capacity enabling strong IPD volume growth of 30% y-o-y c=:>c=:> •
Page 12
12 Key operating metrics: ARPP and revenue mix ARPP growth driven by change in case and payor mix ARPP* (INR Lakh) 26% 11% 4% 3% H1 FY26 55% 27% 11% 4% 3% H1 FY27 56% 25% 12% 4% 11% 5% 3% 3% Q2 FY26 Q1 FY27 56% 27% 10% 4% 55% 3% 26% Q2 FY27 56% IPD Revenue mix by payor category** IPD vs OPD revenue mix Cash TPA CGHS/ ECHS/ Indian Railways PSU & Corporate Others 17% 83% H1 FY26 18% 82% H1 FY27 17% 83% Q2 FY26 18% 82% Q1 FY27 18% 82% Q2 FY27 OPD IPD 7% 93% H1 FY26 7% 93% H1 FY27 7% 93% Q2 FY26 6% 94% Q1 FY27 7% 93% Q2 FY27 International Domestic * ARPP is calculated on Hospital Revenues excluding Other Operating Income and Other Income divided by Inpatient Volumes ** IPD revenue mix by payor category is based on payment type Domestic and international revenue mix 2.01 2.04 2.01 2.02 2.06 H1 FY26 H1 FY27 Q2 FY26 Q1 FY27 Q2 FY27 +1.5% +2.7% • • • • • • • • •
Page 13
13 Diverse revenue1 mix Significant contribution from complex specialties Notes: 1. Revenue from healthcare services excludes other operating income and other income 2. Revenue breakdowns are provided as per internal MIS at the Company’s consolidated level 3. Cancer includes medical oncology, radiation oncology, head & neck surgery, bone marrow transplant and breast surgery 20.4% 20.7% 20.5% 20.5% 21.0% 5.4% 6.3% 5.2% 6.7% 5.9% 5.8% 6.0% 5.8% 5.5% 6.4% 7.5% 8.3% 7.4% 8.2% 8.5% 11.1% 11.0% 11.0% 11.2% 10.9% 11.7% 11.1% 12.1% 11.0% 11.2% 14.3% 13.9% 14.4% 13.5% 14.3% 20.8% 20.3% 20.7% 20.7% 19.8% 3.0% H1 FY26 2.4% H1 FY27 2.9% Q2 FY26 2.7% Q1 FY27 2.0% Q2 FY27 Heart Cancer Digestive Neuro Kidney & Urology Internal Medicine Ortho Liver Transplant Others Speciality
Page 14
14 Cluster 1 hospitals - Consistent Growth with Improved Margin Growth in cluster-1 hospitals led by both patient volume and case mix change Cluster 1 hospitals – Gurugram, Indore and Ranchi 13,778 15,708 6,989 8,229 H1 FY26 H1 FY27 Q2 FY26 Q2 FY27 +14.0% +17.8% 20.1% 22.0% Revenue from operations (INR million) 2,760 3,379 1,402 1,810 H1 FY26 H1 FY27 Q2 FY26 Q2 FY27 +22.4% +29.1% Operating EBITDA (INR million and margin %) Occupied Bed Days (count) ARPP* (INR Lakh) 92,037 99,413 Q2 FY26 Q2 FY27 +8.0% 2.19 2.24 Q2 FY26 Q2 FY27 +2.2% 61% 66% ALOS (days) 2.98 2.80 Q2 FY26 Q2 FY27 -6.1% 20.0% 21.5% In-patient Volume (In ‘000) 31 36 Q2 FY26 Q2 FY27 +15.2% Cluster 1 (previously referred to as "Mature Hospitals") comprises Gurugram, Indore and Ranchi hospitals . The grouping has been renamed for presentation purposes, with no change in the underlying composition. *ARPP is calculated on Hospital Revenues excluding Other Operating Income and Other Income divided by inpatient volumes
Page 15
15 Cluster 2 hospitals - Robust Growth with Improved Margin Inpatient volume growth of 52% and ARPP growth of 8% led to strong revenue and EBITDA growth Cluster 2 hospitals – Lucknow, Patna and Noida 6,744 10,760 3,547 5,790 H1 FY26 H1 FY27 Q2 FY26 Q2 FY27 +59.6% +63.2% 24.7% 31.7% 1,782 3,086 875 1,837 H1 FY26 H1 FY27 Q2 FY26 Q2 FY27 +73.2% +110.0% Occupied Bed Days (count) ARPP* (INR Lakh) 63,692 91,187 Q2 FY26 Q2 FY27 +43.2% 1.75 1.88 Q2 FY26 Q2 FY27 +7.6% 62% 67% ALOS (days) 3.17 3.00 Q2 FY26 Q2 FY27 -5.5% 26.4% 28.7% In-patient Volume (In ‘000) 20 30 Q2 FY26 Q2 FY27 +51.6% *ARPP is calculated on Hospital Revenues excluding OPD Pharmacy and Other Income divided by inpatient volumes Cluster 2 (previously referred to as "Developing Hospitals") comprises Lucknow, Patna and Noida hospitals. The grouping has b een renamed for presentation purposes, with no change in the underlying composition. Revenue from operations (INR million) Operating EBITDA (INR million and margin %)
Page 16
16 H1 FY2027 Balance sheet summary Well capitalized balance sheet and strong EBITDA to cash flow conversion Key Highlights • Gross Debt increased by INR 638 million • Net Cash surplus of INR 7,815 million at the end of 30 September, 2026 • Medanta continues to generate strong operating cash flows, supported by robust EBITDA-to-cash flow conversion of 86% in H1 FY27 • Capex of INR 3,385 million incurred during H1 FY27 • Well capitalized balance sheet to drive future expansion plans and growth INR millions FY2023 FY2024 FY2025 FY2026 H1 FY2027 Gross Debt 8422 4,193 3,279 6,311 6,949 Cash and Cash Equivalents 13,114 11,913 11,402 12,217 14,765 Net Debt / (Net Cash) (4,692) (7,720) (8,123) (5,906) (7,815) Shareholder Equity 24,282 29,056 33,864 39,616 43,234 Net Debt to Equity (x) - - - - - Net Cash flow from Operations 6,445 6,121 6,238 7,144 5,678 Operating EBITDA 1 6,278 7,991 8,771 9,191 6,568 Cash Flow Conversion (%) 102.7% 76.6% 71.1% 77.7% 86.4% Net Debt to EBITDA (x) - - - - - 1. Operating EBITDA is defined as EBITDA excluding other income and after accounting for ESOP expenses. The comparative figures have also been presented on a consistent, like-for-like basis
Page 17
17 Project Update and Capex Plan02
Page 18
18 On-going expansion projects ~20% Capacity added in FY26. Planned bed capacity addition to drive sustainable growth Number of installed beds 3,042 3,665 4,155 7,605 750 750 80 31-Mar-25 623 Bed Addition 31-Mar-26 146 H1 FY27 - Lucknow and Noida Indore Cancer Unit 147 Lucknow 68 Noida 49 Patna FY27e 400 South Delhi Pitampura, Delhi 650 Mumbai Guwahati 400 Varanasi 500 Ghaziabad 623 bed addition +20.5% 490 bed addition +13.4% ~ 3,450 bed addition +83.0% Noida with total capacity of 550 beds: 100 beds added in H1 FY27, taking total bed count to 482 beds at the end of September 2026 Lucknow: 46 Beds added in H1 FY27 taking total bed count of 803 beds. South Delhi: Announced 400 bed in partnership with DLF. Construction is in progress on site 1. Pitampura, New Delhi: O&M Agreement to jointly build and operate & manage a ~750 bed hospital. Revised building plans to be submitted in line with revised NBC standard 2026 Mumbai: Environmental clearance and Consent to Establish received. Piling works for the substructure commenced Guwahati, Assam: Land acquisition completed. Key statutory approvals secured, including Fire, Environmental and Building Plan. On-boarded Consultants for MEP, Facility Planner, and Architecture. Varanasi: 400-bed project announced in March 2026 under built to suit and lease arrangement with developer. Building plans submitted for approval. Indore Cancer Unit: Addition of an 80-bed cancer hospital under business transfer agreement, to be operationalized in Q3 FY27 Ghaziabad: 2.61 acre land parcel allotted in an e-auction. Plan to build ~500 bedded super specialty hospital - ----- -------- ~ --------- ---------C: =--------- ,~ .----:--:--~ c T -------~I--'
Page 19
19 Estimated capex plan Total capex of ~INR 62,390 million planned for next 4 - 5 years 11,000 57,451 62,390 12,175 5,398 8,986 5,898 9,820 Maintenance Capex for 5 Years 425 Lucknow, Patna, Noida and Ranchi New 3,424 South Delhi- DLF Mumbai Pitampura, Delhi Guwahati Varanasi 325 Indore Cancer Unit Ghaziabad 3,000 Medical School 1,939 Guest House Total Capex 3,385 6,000 22,000 10,000 H1 FY2027A H2 FY27E FY28 - 29E FY30E FY31E 62,390 Total Capex 25,000 Project wise capex (INR mn) Year wise estimated capex (INR mn) □ ----------·-I ___ L.._I_ I
Page 20
20 Medanta’s Journey, Purpose and Model of Healthcare 03
Page 21
21 Medanta was founded to bring a new type of healthcare to India… … the human side of healthcare At Medanta we have built an institution to match the highest benchmarks of excellence globally. We have created an ecosystem of excellence that encompasses world-leading clinicians, state-of-the-art equipment, best-in-class infrastructure, and a strong emphasis on research and innovation. Medanta’s patient-first approach allows teams of super-specialist doctors to collaborate seamlessly and arrive at the best-possible treatment customized for each patient in line with our guiding philosophy ‘Har Ek Jaan Anmol’, meaning ‘Every Life is Invaluable’ Dr. Naresh Trehan Healthcare is never only about science. It is also about the art of medicine – the human connection, putting the patient first, collaboration, the personal acts of empathy and the values that guide our decision making. “ “ CMD & Chief Cardiac Surgeon, Medanta
Page 22
22 Growth from a single flagship hospital in Gurgaon… …to a network of 6 high quality hospitals across north India 2013 Carlyle* buys minority stake in December 2015 Temasek buys minority stake in January 2014 MEDANTA SUPER SPECIALTY HOSPITAL INDORE 175 Beds 53 ICU Beds 2009 MEDANTA THE MEDICITY Gurgaon 1,440 Beds 316 ICU Beds 2015 MEDANTA ABDUR RAZZAQUE ANSARI MEMORIAL WEAVERS HOSPITAL RANCHI 200 Beds 54 ICU Beds 2019 MEDANTA HOSPITAL LUCKNOW 950 Beds 803 currently operational including 211 ICU beds 2021 JAI PRABHA MEDANTA SPECIALTY HOSPITAL PATNA 650 Beds 601 currently operational including 176 ICU beds IPO • *Carlyle Group (Anant Investments) exited completely in the IPO FY2026 MEDANTA HOSPITAL NOIDA 550 Beds 482 currently operational including 98 ICU beds 2025 MEDANTA HOSPITAL Ranchi Unit 2 110 Beds Commenced operations in July 2025 2022 Global Health Ltd IPO listed on BSE and NSE on 16th November*
Page 23
23 From our flagship Medicity campus in Gurgaon, we have grown to 3,811 beds across 6 cities Largest private hospital beds in operation under one roof in Delhi (NCR), Uttar Pradesh and Bihar All beds are installed beds as at Sept 30, 2026 LUCKNOW 803 beds; 211 ICU beds (950 planned) RANCHI 310 beds; 102 ICU beds Gurgaon 1,440 beds; 316 ICU beds INDORE 175 beds; 53 ICU beds PATNA 601 beds; 176 ICU beds (650 planned) NOIDA 482 beds; 98 ICU beds (550 planned) ~ d l\!,,,, meoa ma ~ =mF ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ , ............................................................................................................................................... ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
Page 24
24 One of the largest private hospital chains in North and East India Serving over 400 million people in the States with Medanta facilities Existing Hospital : 1. Gurugram, 2. Indore, 3. Ranchi, 4. Lucknow 5. Patna 6. Noida Upcoming Hospitals: 1.Mumbai, 2. Pitampura, New Delhi 3. South Delhi, 4. Guwahati 5. Varanasi Delhi / NCR Uttar Pradesh Lucknow Bihar Patna Madhya Pradesh Indore Jharkhand Ranchi Gurugram Mumbai Maharashtra Assam Guwahati Our Network Hospital Network 6 Multi-speciality hospitals 6 Upcoming hospitals 3,811 Total Beds ~3,800 Planned Bed Addition Bed Capacity 955+ ICU Beds 110 Infrastructure Our People Continuity of care Doctors Nurses and paramedics Full-time and retainer employees Medanta Clinics Medanta Labs Pharmacy 12 Clinics 7 cities 13 Labs total 850+ Pick Up Points 28 Pharmacy 2,580+ 8,210+ 14,500+ Operating Theatres Gurugram; Largest single location private hospital in with operational bed capacity of 1,440Delhi; ~1,150 bed addition planned with 750 beds in Pitampura and 400 beds in South Delhi Mumbai; ~750 beds super speciality hospital under construction at Oshiwara Noida; 550 beds super speciality hospital Guwahati; Planned 650 bed super-specialty hospital to serve entire Northeast region Ghaziabad; Planned 500 beds super speciality hospital Patna; Largest private hospital in Patna with planned bed capacity of 650 Indore; 175 bedded hospital s New 80 bedded hospital to be operationalized under BTA Existing Hospital Medanta Labs Network Medanta Clinics Upcoming Hospital Lucknow; Largest private hospital in Uttar Pradesh with planned bed capacity of 950 Ranchi; 310 beds across two units Noida Varanasi; Planned 400 beds super speciality hospital ' • *
Page 25
25 Our Mission and Values Embracing a new era and redefining our purpose MISSION Our mission is to deliver world class, patient centric, integrated and affordable healthcare through a dynamic institution that focuses on the development of people and knowledge Core Values Patient centric care: Foster a culture where every one of us is committed to care for patients and their caregivers Leadership and quality: Commit to delivering excellence in everything we do through exemplary action and behaviour Collaboration, learning and innovation: Promote teamwork and collaboration, welcome change and creativity, encourage innovation Integrity and courage: Maintain the highest ethical standards by putting the patient first and demonstrating the courage to do what is right ef!: ........................................................................................................................................................... .
Page 26
26 The Medanta Model of Healthcare Delivering the highest quality of medicine with care and compassion What it means for patients and caregivers? • Super specialized doctors provide the highest quality of care through a team based integrated approach • A safe and friendly healing environment with a patient-centric design in all clinical areas and public spaces • Availability of the most advanced, innovative equipment and technology to enable the most complex diagnostics and treatment • Doctors who take ownership and personal responsibility • Respect-based processes for patients and their families Model of Healthcare Exceptional clinical talent World class Infrastructure Latest high end technology Caring systems and processes Trust based compassionate care + meoanTa
Page 27
27 Medanta is well placed to deliver sustainable growth… …while maintaining its core values of patient centric care and clinical leadership and quality In existing and new hospitals BED EXPANSION Engage prominent, skilled clinical talent ATTRACT BEST TALENT Add new specialties and improve operating efficiencies ENHANCE CAPABILITIES Use technology to improve patient experience and grow digital health TECHNOLOGY ADVANCEMENT Extend clinical services outside hospital and across patient lifetime CONTINUITY OF CARE Build on our thought leadership through academics and research THOUGHT LEADERSHIP j'-'i
Page 28
28 Annexures04
Page 29
29 Annexure: Profit and Loss Statement Half Year Quarter INR million H1 FY2026 H1 FY2027 Y-o-Y Growth % Q2FY2026 Q1FY2027 Q2FY2027 Y-o-Y Growth % Revenue from operations 21,301 27,731 30.2% 10,993 13,041 14,690 33.6% Cost of materials consumed 4,946 6,156 24.5% 2,556 2,944 3,213 25.7% Employee benefits expense 8,045 10,550 31.1% 4,193 5,136 5,413 29.1% Other expenses 3,551 4,330 21.9% 1,834 2,029 2,301 25.4% ESOP Expenses 179 127 (29.3)% 100 64 63 (37.2)% Operating EBITDA1 4,580 6,568 43.4% 2,310 2,868 3,701 60.2% Operating EBITDA Margins % 21.5% 23.7% 219 bps 21.0% 22.0% 25.2% 418 bps Other income 401 458 14.1% 197 222 236 20.1% Finance costs 309 548 77.2% 171 267 281 64.1% Depreciation and amortisation expense 948 1,398 47.4% 497 690 708 42.4% Exceptional item (356) - Nm (160) - - nm Profit before tax 4,080 5,081 24.5% 1,998 2,133 2,948 47.6% Tax expenses 906 1,317 45.4% 414 560 757 82.7% Profit after tax 3,174 3,764 18.6% 1,584 1,573 2,191 38.3% 1. Operating EBITDA is defined as EBITDA excluding other income and after accounting for ESOP expenses. The comparative figures have also been presented on a consistent, like-for-like basis - I I I I I I I I __ _ - 1 I ____ _
Page 30
30 Annexure: Operational Parameters • Census Beds as based on monthly average during the period • *ARPP is calculated on Hospital Revenues excluding Other Operating Income and other income divided by Inpatient Volumes; • **Outpatients volume reflects OPD encounters Year End Quarter Key metrics H1 FY2026 H1 FY2027 Y-o-Y Growth % Q2FY2026 Q1FY2027 Q2FY2027 Y-o-Y Growth % Total Beds 3,435 3,811 10.9% 3,435 3,737 3,811 10.9% Census Beds 2,573 3,076 19.6% 2,658 3,037 3,115 17.2% Occupied Bed Days 2,98,627 3,63,664 21.8% 1,55,729 1,73,064 1,90,600 22.4% Occupancy Rate % 63.4% 64.6% 1.8% 63.7% 62.6% 66.5% 283 bps ARPP (INR Lakh)* 2.01 2.04 1.5% 2.01 2.02 2.06 2.7% ALOS (days) 3.04 2.88 (5.3)% 3.06 2.87 2.89 (5.5)% In-Patient Volumes 98,075 1,26,170 28.6% 50,925 60,214 65,956 29.5% Out-Patient Volumes** 17,09,565 23,29,542 36.3% 8,90,750 11,00,928 12,28,614 37.9%
Page 31
31 Annexure: Abbreviations and Definitions Bed Capacity / Installed Beds : Total Bed available in the hospital (including census (bed available for mid-night occupancy) and non-census beds (all other bed available other than census beds, i.e., day-care beds). Occupied beds : Total Count of patients at midnight at each day Average Occupancy Levels : (Total Occupied beds/Total census beds) i.e. Excluding day Care bed, Emergency, Dialysis beds, Pre & post catherization & Observation room ICU Beds: No of ICU Beds available in the hospital out of census beds Total Income : Revenue from Operations + Other Income ARPP : Income from Health Care Services excluding Other Operating Income and Other Income divided by Inpatient Volume ALOS : Average number of days spent by admitted inpatients Revenue mix by Payment Type, i.e. Cash, TPA,CGHS, ECHS, PSU others INR : Indian Rupee NABH : National Accreditation Board for Hospitals & Healthcare Providers NABL : National Accreditation Board for Testing and Calibration Laboratories JCI : Joint Commission International OPD : Out-Patient Department IPD : In Patient Department ICU : Intensive Care Unit Mn : Million ARPP: Average Revenue per Inpatient ALOS : Average Length of Stay Operating EBITDA represents EBITDA excluding other income and after accounting for ESOP expenses. Operating EBITDA Margin : Operating EBITDA divided by Revenue from Operations in percentage PAT : Profit After Tax NCR : National Capital Region Definitions Abbreviations
Page 32
32 Contact us About Medanta Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon who has been awarded the prestigious Padma Bhushan and the Padma Shri, the third- and fourth-highest civilian awards in India, and the Dr. B.C. Roy Award in recognition of his distinguished contribution to medicine. Global Health Limited (the “Company”) is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, with key specialties cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology, according to the report titled “An assessment of the healthcare delivery market in India, September 2022” by CRISIL Limited. Under the “Medanta” brand, the Company has a network of six hospitals currently in operation (Gurgaon, Indore, Ranchi, Lucknow, Patna and Noida). Spanning an area of 5.6 million sq. ft., its operational hospitals have 3,737 installed beds as on June 30, 2026. The Company provides healthcare services in over 30 medical specialties and engages over 2,480 doctors led by highly experienced department heads. Contact Details Gaurav.Chugh@Medanta.org Corporate Office Medanta; The Medicity CH Baktawar Singh Rd, Medicity, Islampur Colony, Sector 38, Gurgaon, Haryana 122001 For further information, please visit our website: https://www.medanta.org/ Bhushan Khandelwal Investor Relations +91 7588844495 Bhushan.Khandelwal@Medanta.org Gaurav Chugh Head Investor Relations +91 99585 88900 • 2.